| Abciximab combined with half-dose reteplase has beneficial effects on inflammatory myocardial response in patients with myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 19786940 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In patients with ST-segment elevation myocardial infarction (STEMI), myocardial reperfusion is associated with an inflammatory response leading to adverse effects on further myocardial damage. Therefore, we investigated the effects of the thrombolytic regimen with half-dose reteplase (r-PA) combined with abciximab on different cytokines involved in the local and systemic inflammatory scenario in STEMI patients. Thirty-eight STEMI patients were enrolled in this study. We investigated the effects of the regimen with half-dose r-PA plus abciximab versus full-dose r-PA on interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), MCP-1 and tumor necrosis factor-alpha (TNF-alpha) up to 48 h after the start of therapy. The full-dose r-PA group had a significant IL-6 increase after 48 h compared with the combination group. Furthermore, the full-dose r-PA group showed a marked increase of IL-10 (up to 3 h after) compared with a 41% IL-10 decrease in the combination group. MCP-1 decreased significantly after 3 h in the combination group compared with patients on r-PA therapy only. The combination group showed a nonsignificant increase in IL-8 within the first 6 h. There were no differences in TNF-alpha levels between the two infarct groups. In vivo, the investigated combined thrombolytic regimen consisting of half-dose r-PA plus abciximab causes less of an IL-6 increase and marked decreases in IL-10 and MCP-1 in STEMI patients compared with the pure r-PA thrombolytic regimen. This observation suggests that besides the known beneficial effects on systemic coagulation and leukocyte-platelet aggregates, this regimen may exert a favorable influence on myocardial tissue damage and thus on cardiac repair following myocardial infarction. |
| | |
Authors:
|
Sebastian Szabo; Diana Etzel; Thomas Walter; Silke Kazmaier; Thomas Oikonomopoulos; Roger Marx; Hans Martin Hoffmeister |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Volume: 20 ISSN: 1473-5733 ISO Abbreviation: Blood Coagul. Fibrinolysis Publication Date: 2009 Mar |
Date Detail:
|
Created Date: 2009-09-29 Completed Date: 2009-12-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9102551 Medline TA: Blood Coagul Fibrinolysis Country: England |
Other Details:
|
Languages: eng Pagination: 129-33 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine II, Klinik für Kardiologie, Städtisches Klinikum, Gotenstrasse 1, Solingen, Germany. KrisztinaSzb@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antibodies, Monoclonal / administration & dosage* Anticoagulants / administration & dosage* Cytokines / blood Dose-Response Relationship, Drug Drug Therapy, Combination Female Fibrinolytic Agents / administration & dosage* Humans Immunoglobulin Fab Fragments / administration & dosage* Inflammation / blood, drug therapy Inflammation Mediators / blood Male Middle Aged Myocardial Infarction / blood, drug therapy* Recombinant Proteins / administration & dosage Regeneration / drug effects* Tissue Plasminogen Activator / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Cytokines; 0/Fibrinolytic Agents; 0/Immunoglobulin Fab Fragments; 0/Inflammation Mediators; 0/Recombinant Proteins; 133652-38-7/reteplase; 143653-53-6/abciximab; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Polymorphisms in exons 6 and 7 of the ABO locus and their association with venous thrombosis in youn...
Next Document: Association of inherited thrombophilia with embryonic and postembryonic recurrent pregnancy loss.